Fact based stock research
Pfizer (NYSE:PFE)


Pfizer stock research in summary

pfizer.com


Pfizer shares have a SELL rating. While they are good value, they show below average growth, and are riskily financed. We recommend selling Pfizer shares.


Latest Obermatt Ranks


Country USA
Industry Pharmaceuticals
Index Dow Jones, S&P 500, D.J. US Pharmaceutical
Size class X-Large

March 22, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Pfizer

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
49
44
49
67
STOCK GROWTH RANKS
7
67
34
34
STOCK SAFETY RANKS
35
23
30
26
COMBINED STOCK RANKS
14
42
5
31

Last update of Combined Rank: 22-Mar-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Pfizer in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 22-Mar-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Pfizer; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
13
68
17
17
PROFIT GROWTH
11
11
11
49
STOCK RETURNS
38
69
53
54
CONSOLIDATED RANK: GROWTH
7
67
34
34

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Pfizer.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
40
33
32
34
REFINANCING
25
22
35
21
LIQUIDITY
46
40
40
40
CONSOLIDATED RANK: SAFETY
35
23
30
26

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Pfizer and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Pfizer from March 22, 2018.